|
LINAGLIPTIN |
| Synonyms. Linagliptin; 8-((3R)-3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-((4- methylquinazolin-2-yl) methyl) purine-2,6-dione; Ondero; Tradjenta; Trajenta; |
|
|
| PRODUCT IDENTIFICATION | |
|
CAS RN |
668270-12-0 |
|
EINECS RN |
|
|
FORMULA |
C25H28N8O2 |
|
MOLE WEIGHT |
472.54 |
|
H.S CODE |
2939.59.9900 |
|
SMILES |
CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC 5=CC=CC=C5C (=N4)C)C |
|
CLASSIFICATION |
Dipeptidyl-Peptidase IV Inhibitor, Protease Inhibitor |
|
EXTRA NOTES |
A dipeptidyl peptidase-4 inhibitor developed for treatment of type II diabetes. |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES | |
|
PHYSICAL STATE. |
yellowish powder |
MELTING POINT |
201 ~ 203 C |
|
BOILING POINT |
|
|
DENSITY |
1.39 |
|
SOLUBILITY IN WATER |
|
| SOLVENT SOLUBILITY | |
|
VAPOR DENSITY |
|
|
log P(octanol-water) |
|
|
VAPOR PRESSURE |
|
|
AUTOIGNITION TEMP |
|
| pKa |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents |
| POLYMERIZATION |
Has not been reported |
|
NFPA RATINGS |
Health: 0, Flammability:0, Reactivity: 0 |
|
|
| EXTERNAL LINKS & GENERAL DESCRIPTION |
||||||||||||||||||
|
Wikipedia Linking - Linagliptin Google Scholar Search - Linagliptin Drug Information Portal (U.S. National Library of Medicine) - Linagliptin PubChem Compound Summary - Linagliptin Drug Bank - Linagliptin KEGG (Kyoto Encyclopedia of Genes and Genomes) - Linagliptin http://www.ebi.ac.uk/ - Linagliptin http://www.ncbi.nlm.nih.gov/ - Linagliptin http://toxnet.nlm.nih.gov/ Local
|
|
|
| SALES SPECIFICATION | |
|
APPEARANCE |
yellowish powder |
|
IDENTIFICATION |
Pass HPLC, IR |
|
ASSAY |
98.5% min |
|
MELTING POINT |
201 - 203 C |
|
IMPURITY |
1.5% max (total), 0.5% max (Individual) |
|
LOSS ON DRYING |
1.0% max |
|
RESIDUE ON IGNITION |
0.1% max |
|
HEAVY METALS |
20ppm max |
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
Not regulated |
| HAZARD CLASS |
|
| PACKING GROUP | |
|
|
| SAFETY INFORMATION |
|
|
HAZARD OVERVIEW |
Avoid contact and inhalation. May causes eye irritation. May causes skin irritation. May cause gastrointestinal irritation. May causes respiratory tract irritation |
| HAZARD CODES |
|
|
RISK PHRASES |
|
|
SAFETY PHRASES |
22-24/25 |
|
|
| PACKING |
|
|
|
|
| PRICE INFORMATION |
|
|